Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.55 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | SLC18A3 | Q16572 | 7/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DHFR | P00374 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.48 |
| ▸ | HTR3B | O95264 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.48 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5919209 | 0.88 | SLC18A3 (0.47) | MBTD1L3MBTL3L3MBTL1SLC18A3GRIN2B | |
| SCHEMBL16669158 | 0.88 | NOTUM (0.53) | MBTD1L3MBTL3L3MBTL1SLC18A3CYP1A2 | |
| SCHEMBL939776 | 0.87 | SLC18A3 (0.52) | MBTD1L3MBTL3L3MBTL1SLC18A3GRIN2B | |
| SCHEMBL8363020 | 0.87 | LMNA (0.49) | SLC18A3GRIN2BDRD2SMN1; SMN2ADRB1 | |
| SCHEMBL31612521 | 0.87 | MEN1 (0.61) | SLC18A3DRD2DRD4SIGMAR1CYP1A2 | |
| SCHEMBL23655985 | 0.87 | SLC18A3 (0.47) | MBTD1L3MBTL3L3MBTL1SLC18A3DRD2 | |
| SCHEMBL241159 | 0.87 | DHFR (0.50) | L3MBTL1SLC18A3GRIN2BDRD2DHFR | |
| SCHEMBL16763481 | 0.87 | SLC18A3 (0.47) | MBTD1L3MBTL3L3MBTL1SLC18A3GRIN2B | |
| SCHEMBL5546675 | 0.87 | ME3 (0.54) | SLC18A3DRD4CYP2D6CYP1A2CYP2C9 | |
| SCHEMBL6132832 | 0.85 | SIGMAR1 (0.63) | SLC18A3SIGMAR1TSHRSMN1; SMN2HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024248132-A1 | METAL PATTERNING MATERIAL, HETEROCYCLIC COMPOUND, THIN FILM FOR METAL PATTERNING, ORGANIC ELECTROLUMINESCENCE ELEMENT, ELECTRONIC APPARATUS, AND METAL PATTERN FORMATION METHOD | 東ソー株式会社 | 2024-12-05 | — | — | WO | disclosed |
| CN-118598798-A | Preparation method for directly synthesizing arylamine compound based on aromatic hydrocarbon and fatty amine | 沈阳药科大学 | 2024-09-06 | — | — | CN | disclosed |
| CN-106413717-A | Pharmaceutical compositions | 查尔斯顿实验室公司 | 2017-02-15 | — | — | CN | disclosed |
| CN-1178906-C | N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases | ���Ͽع�����˾ | 2004-12-08 | — | — | CN | disclosed |
| EP-1001930-B1 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LAB (US) | 2002-12-04 | — | — | EP | disclosed |
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | DAVIDSEN STEVEN K (US) | 2002-01-17 | — | — | US | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
| US-6235786-B1 | RHEUMATIC DISORDERS; BONE DISORDERS; ORAL DISEASES; ANTIULCER AGENTS; ANTITUMOR AGENTS | ABBOTT LABORATORIES | 2001-05-22 | — | — | US | disclosed |
| CN-1261876-A | N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases | ABBOTT LAB (US) | 2000-08-02 | — | — | CN | disclosed |
| EP-1001930-A2 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | Abbott Laboratories (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006361-A2 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | MMP1, MMP9, MMP3 | MBTD1 1297/4885L3MBTL3 4274/4885L3MBTL1 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.